Page 130 - ASHG 2013 Program Guide

INVITED AND PLATFORM SESSIONS  
 117
Taking photographs or sound recordings in all meeting rooms is strictly prohibited. Thank you for your cooperation.
INVITED AND PLATFORM SESSIONS
Friday, October 25
2:00
PM
–4:15
PM
Concurrent Platform (abstract-driven)
Session E (54-62)
SESSION 59 – Prenatal and Reproductive Genetics
Room 253, Level 2, Convention Center
Moderators
:
David Chitayat, Mount Sinai Hosp.,
­
Toronto; Mary E. Norton, Stanford Univ.
376
/2:00
Noninvasive fetal trisomy test: A large-
scale clinical practice in 78,289 cases.
F. Chen, X.
Pan, X. Li, H. Ge, S. Chen, H. Jiang.
377
/2:15
Comparison of three single-cell whole
genome amplification methods for detection of
genomic aberrations by array CGH: A step towards
noninvasive prenatal diagnosis using intact fetal
cells.
A. Breman, W. Bi, C. A. Shaw, I. Van den Veyver,
C. J. Shaw, A. Stubbs, M. Withers, G. Fruhman, A.
Patel, J. R. Lupski, A. Beaudet.
378
/2:30
Next-generation sequencing based
preimplantation genetic testing of 24-chromosome
aneuploidy and monogenic disorders.
N. R. Treff, X.
Tao, A. Fedick, D. Taylor, K. H. Hong, E. J. Forman, R.
T. Scott, Jr.
379
/2:45
Genetic normalization of differentiating
aneuploid cleavage stage embryos.
P. R. Brezina,
R. Ross, A. T. Benner, R. P. Dicky, R. Kaufmann, R.
Anchan, Y. Zhao, A. Barker, K. J. Tobler, G. R. Cutting,
W. G. Kearns.
380
/3:00
Maternal age dependent loss of SMC1
b
transcripts in human oocytes.
V. Jobanputra, S. K.
Nurudeen, M. Shirazi, R. W. Prosser, A. Naini, J. K.
Kline, M. V. Sauer, D. Warburton.
381
/3:15
A clinical algorithm for efficient, high-
resolution cytogenomic analysis of uncultured
perinatal tissue samples: Study of more than 700
cases.
G. Maire, A. Xuan Tong Yu, E. Kolomietz.
382
/3:30
Whole genome oligonucleotide-SNP arrays
in prenatal diagnosis: advancement in identification
of clinically significant chromosomal abnormalities.
T. Sahoo, L. P. Ross, K. A. Kopita, L. W. Mahon, J.-C.
J. Wang, M. Hemmat, B. T. Wang, F. Z. Boyar, M.
Haddadin, M. M. Elnaggar, R. Owen, A. Anguiano.
383
/3:45
The fetal
FMR1
premutation phenotype:
Clues from the amniotic fluid transcriptome.
L. M.
Zwemer, S. L. Nolin, P. Okamoto, M. Eisenberg, D. W.
Bianchi.
384
/4:00
The wide spectrum of alpha and beta-
tubulinopathies in foetus : From microlissencephaly
to asymmetrical multifocal polymicrogyria.
N.
Bahi-Buisson, K. Poirier, C. Fallet-Bianco, Y. Saillour,
S. Valence, N. Lebrun, M. Ossando, F. Razavi, T. Attie
Bittach, F. Guimot, S. Blesson, B. Doray, B. Lhermitte,
E. Andrini, P. S. Jouk, C. Rouleau, M. C. Addor,
F. Jossic, P. Marcorelles, L. Loeuillet, A. Gelot, A.
Laquerriere, L. Pinson, P. Loget, F. Chapon, P. Dias,
N. Revencu, F. J. Fourniol, C. Beldjord, J. Chelly.
Friday, October 25
2:00
PM
–4:15
PM
Concurrent Platform (abstract-driven)
Session E (54-62)
SESSION 60 – Ethical, Legal, Social and Policy Issues
Room 258, Level 2, Convention Center
Moderators
:
Dawn Allain, The Ohio State Univ.;
­
Barbara Biesecker, NHGRI/NIH
385
/2:00
Practical assessment of incidental
finding recommendations for use in clinical exome
testing.
M. C. Dulik, E. T. DeChene, L. K. Conlin, S.
Mulchandani, A. Santani, J. L. Abrudan, M. J. Italia,
M. Sarmady, J. C. Perin, B. Bernhardt, C. A. Stolle,
R. E. Pyeritz, A. Wilkens, S. E. Noon, P. S. White, I. D.
Krantz, N. B. Spinner.
386
/2:15
Individual expectations for return of
secondary results from exome sequencing.
H.
K. Tabor, J. Crouch, A. A. Lemke, K. M. Dent, A. G.
Shankar, S. M. Jamal, J. H. Yu, M. J. Bamshad.
387
/2:30
The benefits and risks of wanting it all:
How parents plan to manage their children’s
exome sequencing results.
J. Yu, J. Crouch, A. A.
Lemke, A. G. Shankar, K. M. Dent, M. J. McMillin, S.
M. Jamal, M. J. Bamshad, H. K. Tabor.
388
/2:45
Evaluation of clinical utility of whole
genome sequencing: The WGS500 programme.
J.
Taylor, G. McVean, A. Wilkie, J. Bell, P. Ratcliffe, D.
Bentley, P. Donnelly, WGS500 Consortium.
389
/3:00
International views on sharing incidental
findings from whole genome research.
A.
Middleton, M. Parker, E. Bragin, C. F. Wright, H. V.
Firth, M. Hurles, DDD Study.
390
/3:15
No evidence for increase in screening
among women given report of moderately higher
than average risk for breast cancer from personal
genomics services: The PGen Study.
S. W. Gray, H.
Q. Rana, S. Gollust, C. A. Chen, S. Kalia, J. Mountain,
T. Moreno, J. S. Roberts, R. C. Green, for PGen Study
Group.
391
/3:30
Context is complex: Attitudes to
incorporating genomic risk profiling into population
screening programs.
S. G. Nicholls, H. Etchegary, J.
C. Carroll, D. Castle, L. Lemyre, B. K. Potter, J. Little,
B. J. Wilson, on behalf of CIHR Emerging Team in
Genomics and Screening.
392
/3:45
How do citizens balance the benefits
and burdens of newborn screening? A choice
experiment.
F. A. Miller, R. Z. Hayeems, Y. Bombard,
C. Cressman, C. J. Barg, J. C. Carroll, B. Wilson,
J. Little, D. Avard, J. Allanson, P. Chakraborty, Y.
Giguere, D. A. Regier.
393
/4:00
Identifying genetic relatives without
compromising privacy.
E. Eskin, D. He, N. Furlotte,
R. Ostrovsky, A. Sahai.